Precautions for taking Paquintinib: risk of bleeding, cardiac toxicity, and gastrointestinal reactions
The use of Pacritinib should focus on three major types of adverse reactions: bleeding risk, cardiac toxicity, and gastrointestinal reactions, and graded management measures should be taken according to the severity of symptoms. The following provides a detailed explanation of precautions in terms of monitoring requirements, intervention measures, and dosage adjustments.
1. Bleeding risk management
(1) Absolute contraindication: Patients with active bleeding or platelet count<50 × 10 ⁹/L are prohibited from using medication, and medication should be suspended before and after surgery.
(2) Monitoring requirements: During the treatment period, platelet count should be checked weekly. If bleeding symptoms such as bruising and nosebleeds occur, seek medical attention immediately.
(3) Intervention measures: Treatment should be interrupted for bleeding of grade 2 or above, and platelet transfusion or fresh frozen plasma should be administered if necessary.
Prevention and control of cardiac toxicity
(1) Taboo population: Patients with severe heart block and uncontrolled arrhythmia are prohibited from using it.
(2) Monitoring requirements: Baseline and monthly follow-up electrocardiograms should be conducted to monitor changes in QT interval (>500ms should be discontinued).
(3) Electrolyte management: Maintain blood potassium levels above 4mEq/L and blood magnesium levels above 1.8mg/dL, and avoid the use of QT prolonging drugs in combination.
3. Treatment of gastrointestinal reactions
(1) Diarrhea management: Loperamide should be used for grades 1-2, and for grade 3, administration should be suspended and intravenous fluid replacement should be administered.
(2) Nausea control: Ondansetron is preferred, and dexamethasone can be used in combination for stubborn symptoms.
(3) Perforation risk: If there is abdominal pain or fever, intestinal perforation should be investigated, and medication should be permanently discontinued after diagnosis.
4 Other important matters
(1) Drug interactions: Avoid using potent CYP3A4 inhibitors in combination and reduce dosage by 50% if necessary.
(2) Special population: Prohibited during pregnancy, breastfeeding is prohibited within 7 days after discontinuation of medication.
(3) Liver function monitoring: Patients with moderate to severe injuries need to reduce their dosage and undergo monthly ALT/AST testing.
Disclaimer：《Precautions for taking Paquintinib: risk of bleeding, cardiac toxicity, and gastrointestinal reactions》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！